Headline News

Humana (HUM)

Humana Profit Up

Humana said Monday that it had third-quarter net income of $301.5 million, or $1.78 per share, compared with $183 million, or $1.09 per share, a year earlier. Revenue rose 8 percent to $7.72 billion.
Analysts had expected $7.82 billion in revenue.

Nov 2 · 1:01:00 PM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Aetna (AET)

Aetna Earnings, Revenues Up; Top Estimates

Aetna said today that its third-quarter net income climbed 18 percent to $326.2 million, or 73 cents a share, from 277.3 or 58 cents per share. Revenue rose 9% to 8,704.4 million from 7,981.4 million.
Results beat analysts' forecasts.

Oct 29 · 11:03:00 AM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

WellPoint Health Networks (WLP)

Wellpoint Profit Down, But Tops Estimates

Wellpoint said that third quarter earnings of $730.2 million, or $1.53 a share, down from $820.7 million, or $1.60 a share, a year earlier. Revenue rose 3.1% to $15.43 billion
Company's CEO said the nation's largest health insurer by members remains confident about the outlook for the current quarter and expects net growth of more than 400,000 national members in January.

Oct 28 · 10:46:00 AM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Glaxosmithkline Plc (GSK)

Glaxosmithkline Profit Up, Tops Estimates

Glaxosmithkline said its third quarter net income increased 30 percent to 1.34 billion pounds ($2.18 billion) from 1.03 billion pounds a year earlier. Third- quarter revenue advanced 15 percent to 6.76 billion pounds, from 5.88 billion pounds,
Revenues topped the 6.75 billion-pound analyst estimates.

Oct 28 · 10:17:00 AM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Merck (MRK)

Merck Earnings and Outlook Up

Merck & Co.'s (MRK) third-quarter profit more than tripled on a gain from the sale of the drug maker's stake in an animal-health joint venture, while a continued rebound in a blockbuster asthma drug helped overall sales inch higher.
For the three months ended Sept. 30, Merck reported net income of $3.4 billion, or $1.61 a share, up from $1.09 billion, or 51 cents a share, a year earlier. The latest quarter included a gain of $1.7 billion from Merck's sale of its 50% interest in the Merial animal-health joint venture to Sanofi-Aventis SA (SNY), which already owned the other half.

Oct 22 · 9:24:00 AM · Source: Wall Street Journal
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Pfizer (PFE)

Pfizer Profit Up, Sales Slide

Pfizer Inc. on Tuesday posted a higher third-quarter profit despite the recession, as sharp cost cuts made up for a dip in sales.
The maker of cholesterol fighter Lipitor, impotence treatment Viagra and smoking cessation drug Chantix slashed costs on everything from manufacturing and marketing to research and development to produce a profit of $2.88 billion. That was up 26 percent from $2.28 billion a year earlie

Oct 20 · 12:24:00 PM · Source: AP
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Pfizer (PFE)

Pfizer To Close Wyeth Deal Tomorrow After Approval

Pfizer Inc. has won U.S. and Canadian regulatory approval for its $68 billion acquisition of Wyeth. The companies plan on closing the deal tomorrow. Pfizer won U.S. clearance after agreeing to sell half of Wyeth’s animal health business to Boehringer Ingelheim GmbH within 10 days of the acquisition’s closing, the Federal Trade Commission said today in a statement.
Pfizer agreed in January to buy Wyeth in a stock-cash transaction that would give it access to the depression treatment Effexor and pneumonia vaccine Prevnar.

Oct 14 · 2:13:00 PM · Source: Bloomberg · Related: Wyeth
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Abbott Labs (ABT)

Abbott Beats Expectations and Boosts '09 Forecast

Abbott Laboratories (ABT) reported a 36% increase in third-quarter profit, exceeding Wall Street expectations. The company also also boosted its financial forecast for 2009. The company's Q3 profit was boosted by higher sales of nutritional products and heart devices and accelerating sales growth for its top drug, arthritis treatment Humira.
Abbott's good news was another factor in the Dow Jones heading to 10,000.

Oct 14 · 11:36:00 AM · Source: Dow Jones News Wire
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Previous · Next